Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Remifentanil Requirement in Patients Receiving Surgical Treatment of Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01992692
Recruitment Status : Completed
First Posted : November 25, 2013
Last Update Posted : November 25, 2013
Sponsor:
Information provided by (Responsible Party):
Jia-feng Wang, Changhai Hospital

Brief Summary:
Parkinson's disease (PD) is one the main neurodegenerative disease with an incidence of about 3% in patients older than 65 years. Anesthesia in PD patients has been focused by several studies for concerning the interactive reaction between anesthetics and anti-Parkinsonian medication or Parkinsonian symptoms. However, our previous experience showed that the patients undergoing pulse generator placement were more prone to be involved in delayed emergence in the recovery room, which had been not reported yet. We speculated that PD patients might be a special population with abnormal pharmacodynamic characters of anesthetics, though no related evidence could be found to support this hypothesis. Therefore, in this project we investigated whether remifentanl requirement to inhibit patients' response to trachea intubation and skin insertion in PD patients undergoing DBS and pulse generator placement was different from non-PD patients undergoing intracranial surgery for reasons other than PD.

Condition or disease
Parkinson's Disease

Layout table for study information
Study Type : Observational
Actual Enrollment : 62 participants
Observational Model: Case-Control
Time Perspective: Prospective
Study Start Date : January 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine


Group/Cohort
PD group
Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
non-PD group
Non-Parkinsonian patients undergoing intracranial surgery



Primary Outcome Measures :
  1. Concentrations required to inhibit response to trachea intubation and skin incision [ Time Frame: Anesthesia induction to 5min after skin incision ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement, as well as non-Parkinsonian patients undergoing intracranial surgery
Criteria

Inclusion Criteria:

  • Adult Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
  • Adult non-Parkinsonian patients undergoing intracranial surgery

Exclusion Criteria:

  • ASA score higher than Class II
  • predicted difficult airway
  • alcohol or drug abuser
  • informed consent was not provided

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01992692


Locations
Layout table for location information
China, Shanghai
Department of Anesthesiology, Changhai Hospital
Shanghai, Shanghai, China, 200433
Sponsors and Collaborators
Changhai Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jia-feng Wang, Dr., Changhai Hospital
ClinicalTrials.gov Identifier: NCT01992692    
Other Study ID Numbers: Parkinson-remifentanil
First Posted: November 25, 2013    Key Record Dates
Last Update Posted: November 25, 2013
Last Verified: June 2013
Keywords provided by Jia-feng Wang, Changhai Hospital:
Parkinson's disease
remifentanil
deep brain stimulator
cardiovascular response
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases